All Posts

by Vista Partners LLC November 11, 2025

Lovable’s AI Surge: How the Swedish Startup Blitzed to 8 Million Users (and Investor Euphoria) -( $META $NVDA $GOOG )

Lovable, the Stockholm-based AI coding platform, is making headlines after closing in on eight million users and securing a remarkable $228 million in funding—surely enough pocket change to keep the espresso machines humming for every developer north of Berlin. In a market where startups regularly emerge and vanish faster than a TikTok trend, Lovable’s meteoric ascent has left Silicon Valley’s elite clutching their monocles in surprise.

Startup Growth That Defies Gravity

Founded barely a year ago, Lovable now boasts a runaway user tally, up from just 2.3 million in July to nearly eight million by November—a jump steep enough to make most SaaS founders hope the seatbelts are properly fastened. Each day, 100,000 new products are reportedly built using Lovable’s platform, which invites anyone to become a “vibe coder”—no actual coding prerequisite required. For those keeping score at home, that’s about one new app every 0.8 seconds. Even the most caffeinated engineers might struggle to keep pace.

Funding Finesse and Investor FOMO

After announcing a $200 million raise at a $1.8 billion valuation this summer—led by Accel and not, as previously rumored, by a benevolent Swedish prince—Lovable finds itself beset by unsolicited offers from investors hoping to catch a ride before the rocket reaches a rumored $5 billion valuation. CEO Anton Osika insists the company is “not capital constrained,” leaving analysts to wonder if Lovable plans to buy a controlling share in the Scandinavian furniture market just for sport.

The Vibe Coding Boom—and the Sighs of Caution

This explosion of “vibe coding”—apps generated from simple English prompts—is changing the software development landscape. Even Fortune 500 companies have joined the party, hoping Lovable can supercharge their teams’ creativity without the messy side effects of caffeine withdrawal or code review fatigue. Still, research from Barclays suggests that site traffic to Lovable and its peers peaked months ago before slipping back by around 40%. Is “vibe coding” a revolution, or just a particularly groovy phase before everyone remembers they do, in fact, need programmers?.

Competitors and the Fight for Relevance

Lovable’s model faces serious competition: Replit, StackBlitz, OpenAI’s latest playground, and Google’s Firebase Studio all want a piece of this market, and none are shy about deploying AI to make app development less cryptic than a teenager’s text messages. In recognition of these shifting sands, even established tech giants are recalibrating their hiring practices, with some laying off junior coders as AI-generated code grabs the spotlight.

What’s Next For Lovable?

Lovable’s next steps remain deliciously vague—Osika isn’t sharing new revenue details, perhaps preferring to preserve an air of mystery worthy of a Nordic detective series. But with a user base blitzing past eight million and the investment world in a collective swoon, Lovable’s story looks set to continue at breakneck speed. The only question remaining: when the next big lull hits, will anyone remember how to write a for-loop by hand? As Lovable reassures investors and developers, the answer—much like its code—remains beautifully, playfully, open to interpretation.

The Sources…

by Vista Partners LLC November 10, 2025

Stocks Soar With Shutdown Relief Outlook Surfaces On Monday -( $AVGO $EPRX $INTG $LLY $NOK $NVDA $OPEN $PLTR $RIO $SER $SPY $TSLA Rise!)

Stocks soared Monday, November 10, 2025, with a rally that could make even the most seasoned bear consider a hibernation sabbatical. Wall Street’s major indexes leapt as Congress inched closer to ending the record-breaking government shutdown, unleashing the kind of risk-on mood that calls for celebratory confetti—preferably recycled from last week’s shredded retail reports. Also, with AI stocks soaring today, the government dusting off its economic calculators, and the gold bugs dancing, Monday offered market watchers just enough drama to make the wait for delayed data seem almost entertaining. Investors can only hope Congress keeps the shutdowns as rare as a unicorn sighting—and leaves the market fireworks to Wall Street.

Index Performances

S&P 500 climbed 103.63 points, or 1.54%, to 6,832.43, led by consumer and tech titans flexing post-shutdown optimism.
Dow Jones Industrial Average gained 381.53 points, or 0.81%, closing at 47,368.63, with airlines and restaurant giants feasting on stimulus rumors like it’s Thanksgiving early.
Nasdaq Composite roared 522.64 points higher, rising 2.27% to finish at 23,527.17, thanks to AI and chip stocks leading a comeback worthy of a Silicon Valley reboot.
Russell 2000 index advanced 22.82 points, or 0.94%, to 2,455.65, with small caps playing catch-up as risk appetite returned.

Macroeconomic and Fed Reports

Monday delivered little in the way of fresh macro data—thanks, government shutdown!—but optimism is high for a bevy of backlogged reports to follow once the lights are on at the Bureau of Labor Statistics. The latest ADP private payrolls showed a solid 42,000 increase for October, keeping interest rate cut hopes alive, while the September jobs report (finally!) is expected to arrive imminently.

Treasury yields rose, with the 10-year closing at about 4.121%, the 2-yr at 3.601%, and market watchers now pencil in nearly a 60% chance of a Fed rate cut next month. FOMC’s next scheduled rate decision comes in December, and the bond market seems determined to front-run the Fed’s dovish pivot. Tariff news was equally dramatic: Supreme Court justices expressed skepticism over the legal basis for Trump-era Section 301/IEEPA tariffs, suggesting possible refunds of $130-$140 billion—though fiscal impact is expected to be modest.

Commodities and Crypto

Gold hit a two-week high, trading above $4,123.40 per ounce as traders priced in reopening hopes and more dovish Fed action.
Silver rallied to50.405 per ounce.
Crude oil bounced but remained rangebound amid broader commodity volatility closing at $60.05/bbl.
Bitcoin rebounded ~1.79% to $105,890, with bullish sentiment returning after a surprise dip below $100,000 last week and traders pining for a year-end run toward $150,000.

Corporate News and Stock Highlights

Eli Lilly (LLY) surged 4.8% to a record $969.14 after an analyst upgrade and a landmark Medicare pricing deal for GLP-1 drugs, cementing its place atop the obesity and diabetes therapeutics mountain.
NVIDIA (NVDA) jumped ~5%, leading the AI rebound and riding momentum into tomorrow’s catalyst-heavy earnings and partnership news with OpenAI—a pivotal week for the chip champ.
Apple (AAPL), Meta (META), Broadcom (AVGO), and Tesla (TSLA) joined the “Magnificent Seven” revival. Tesla rose 3.6% despite executive exits and China sales hitting a three-year low—fear not, Elon’s drama remains bullish for volatility traders. Meta secured a rating upgrade, despite being the year’s “Magnificent Seven” doormat after a bout of aggressive AI spending; cue the Mark Zuckerberg meme parade.
Palantir Technologies (PLTR) led S&P gainers, up 8.81% as investors bet on its government and White House ties, data contracts, and bold AI ambitions.
Broadcom (AVGO, +2.56%) basked in bullish analyst target hikes fueled by its OpenAI partnership for custom AI chips.
OKLO (OKLO) slipped 1% amid investor jitters, pending an earnings call tomorrow, but made headlines with a $2 billion nuclear fuel partnership and remains up 425.29% YTD.
Opendoor (OPEN, $7.97, +21.49%), Nokia (NOK, +1.90%), McDonald’s (MCD, -.19%), Rio Tinto (RIO, $70.29, +1.38%, Oracle (ORCL, +.66%), and Intel (INTC, +.84%) saw mixed action, with Nokia riding 5G expansion news in Latin America, Oracle weathering insider selling, and McDonald’s surfing alongside broader consumer and restaurant sector strength

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.5095)), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.23, +14.84%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.5008), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR, $1.47, +5%) and M2i Global, Inc. (MTWO) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.99, +2.05%) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $36.88, +1.60%) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

by Vista Partners LLC November 10, 2025

Navitas Semiconductor’s $100M Raise: Powering the Next Wave of AI Chips -( $NVTS $SPY )

Navitas Semiconductor (NVTS, $9.58, +22.19% currently on Monday) turned up the voltage on Wall Street’s risk tolerance last week, announcing a $100 million private placement that, if nothing else, once again proves the semiconductor crowd is not afraid to mix science with spectacle. The Torrance, California–based power IC specialist, best known for gallium nitride (GaN) and silicon carbide (SiC) wizardry, sealed the deal to sell nearly 14.8 million shares of Class A stock at $6.75 per share—a discount that would make even a discount retailer blush, especially as shares wobbled at $8.84 midweek after a head-spinning 34% slide following a previous 352% meteor ride.

Financing the Big “Navitas 2.0” Dream

The company candidly describes the capital raise as rocket fuel for “Navitas 2.0,” a strategic U-turn targeting the sorts of high-power markets you’d expect from a tech firm with vaulting ambitions and a taste for next-gen acronyms: AI data centers, grid infrastructure, and industrial electrification all get billing in the new manifesto. CEO Chris Allexandre, never one for understatement, cited the need to “accelerate our momentum into higher-power markets,” adding a tone of Silicon Valley bravado possibly powered by a few GaN chips of his own.

Numbers, Volatility, and the Margins

On the numbers front, Navitas is brandishing a current ratio close to 8—a financial buffer beefy enough to handle an R&D lab explosion or, more likely, to maintain expansion as it pivots away from low-margin consumer gadgets toward high-wattage grid and AI applications. It’s a necessary shift, as Q3 saw mobile and consumer sales—a sector described by one analyst as “the grownup’s equivalent of selling lemonade at a loss”—down 53% year over year. The $100 million is believed to boost high-voltage R&D, expand production for industrial modules, and help the firm recover from a shareholder hangover triggered by a recent tumble (because nothing says “new era” like issuing a pile of new shares to old investors who just saw their stakes diluted).

Strategic Partners and Industry Positioning

Navitas’ expansion plan is not entirely “Field of Dreams”–grade optimism; the company is quietly aligning with power players like NVIDIA, selling modules that hope to power AI barns and keep data centers sucking up electrons with greater efficiency. Holding a stash of over 300 patents and boasting a “world’s first CarbonNeutral-certified semiconductor” label, it stands as the rare chip company that tries to balance wattage with wokeness.

The Sum…

For now, investors face a classic Wall Street conundrum: Can the company’s high-voltage pitch outpace its habit of net losses, or will it all short-circuit before the next round of fundraising? With ~$150.6 million in the cash drawer and analysts projecting gross margins ticking up as consumer contracts phase out, at the very least, Navitas has bought itself another season in the big leagues.

After all, if the passage to “Navitas 2.0” demands cash, charisma, and a thick-skinned investor base, at least one of those currencies has just been substantially replenished.

The Sources

by Vista Partners LLC November 10, 2025

Biotech Market Movers: Cogent Biosciences and GeoVax Labs Unveil Clinical Wins and Vaccine Innovation -( $COGT $GOVX $IBB $XBI )

Cogent Biosciences (COGT) and GeoVax Labs (GOVX) offered investors and clinicians fresh cause for cautious celebration this week, both releasing data-laden news that—if not quite cocktail-hour material—could at least liven up a Monday earnings call with a smidgen of biotech bravado.

Cogent Biosciences: The Tumor Tango

Cogent Biosciences waltzed onto the market stage with positive Phase 3 results for its bezuclastinib-sunitinib duet in second-line gastrointestinal stromal tumors (GIST). In true headline-making fashion, Cogent’s trial didn’t just move the needle—it demanded a spotlight. Patients prescribed the drug combo, presumably with equal measures of hope and trepidation, saw median progression-free survival double to 16.5 months versus 9.2 months for those on sunitinib alone. Objective response rates were just as dazzling—46% for the duo versus 26% for the solo act, giving statisticians and bullish shareholders simultaneous palpitations, the good kind.

With Wall Street’s favorite narrative arc—namely, “disruptive innovation” plus “share price fireworks”—Cogent CEO Andrew Robbins declared the results “historic,” a sentiment usually reserved for spacecraft landings, not Phase 3 trial readouts. Wall Street rallied accordingly, sending shares higher with the kind of exuberance not seen since caffeine futures rallied after the last inflation print.

GeoVax & World Immunization Day

GeoVax Labs took a different tack, recognizing World Immunization Day by spotlighting its work on next-generation multi-antigen COVID vaccines. The company took pains to note its approach doesn’t just chase the prevailing variant du jour—it aims to offer enduring protection, particularly for immunocompromised individuals who, one suspects, would prefer their antibodies served in robust, multi-antigen cocktails anyway.

CEO David Dodd shared recent safety and efficacy data, underlining that trial subjects suffered no serious vaccine-related adverse events—a clinical outcome so rare. GeoVax’s safety profile overall suggests the biotech might soon be elevating standard COVID protection beyond “good enough,” much to the relief of most trial-weary epidemiologists.

Market Wisdom: Optimism on Tap

While markets rarely hand out “feel-good” days to the biotech sector, Cogent and GeoVax demonstrated that sometimes two press releases really can make Monday look a little less like a repeat episode and a little more like a pilot for the next big hit. Cogent eyes a first-half 2026 FDA submission, while GeoVax tempts investors with the prospect of next-level vaccines, reminding us that optimism—not just good data—remains the day trader’s favorite superpower.

The Sources

by Vista Partners LLC November 10, 2025

Former Lilly Leaders Launch 501 Ventures to Drive Next-Gen Obesity, Diabetes, & Metabolic Breakthroughs – ( $AZN $LLY $NVO $MTSR $MODD )

Two veterans of Eli Lilly’s diabetes business have a fresh diagnosis for the biotech world: more science, less ceremony. Enrique Conterno and Meg Powell, former senior leaders at Lilly, have teamed up to launch 501 Ventures, a new venture capital firm devoted to “advancing the science” of metabolic health.

The duo is betting that the GLP-1 era—driven by blockbusters such as Lilly’s Mounjaro and Novo Nordisk’s (NVO) Wegovy—is merely the first act in a far longer performance. “Some people think the metabolic health story has been written,” Conterno said during an interview at this year’s ObesityWeek conference in Atlanta. “It’s still going to be written.”

From Big Pharma to Venture Capital

Conterno, who led Lilly Diabetes and Lilly USA before serving as CEO of FibroGen, now chairs 501 Ventures while also sitting on Zealand Pharma’s board. Powell, also a Lilly alum, later held roles at GSK, Aerial BioPharma, and Target PharmaSolutions. Together, they bring both commercial know-how and scientific insight to the firm.

Their partnership comes with a playful twist. The firm’s name—501 Ventures—pays homage to U.S. Route 501, the road connecting Duke University and the University of North Carolina at Chapel Hill. Conterno, a Duke graduate, and Powell, a proud Tar Heel, admit their school rivalry still colors their collaboration. “We have a bit of a rivalry,” Conterno joked.

Betting on Early-Stage Science

The 501 team plans to invest primarily in early-stage biotech startups developing next-generation medicines for obesity and metabolic health. Target projects are those a few years from the clinic—programs that need both capital and guidance to determine if they truly stand apart.

Powell says the firm’s mission is to keep investments focused on data rather than bureaucracy. “As soon as you figure out that they’re not best-in-class, shelve them,” she said, emphasizing a disciplined and scientific approach over investor hype.

While the firm has not disclosed its fundraising figures, Powell noted that 501 Ventures is engaging with biopharma companies eager for a front-row seat to emerging science. “So much of what happens in biotech fundraising goes to overhead instead of doing the science,” she said. “We’re committed to fixing that.”

The Global Hunt for Innovation

Conterno and Powell plan a global search for promising research hubs. They cited Boston, San Francisco, San Diego, Shanghai, Tokyo, and Copenhagen as key regions of focus, with Indianapolis receiving an honorable mention thanks to their shared Lilly heritage.

Beyond new drugs, the metabolic health ecosystem continues to evolve through device innovation. Modular Medical (MODD), a California-based medtech company, is making progress with its Pivot Insulin Delivery System—a simplified, next-generation insulin patch pump designed to eliminate many of the usability barriers of traditional pumps. The company recently announced progress toward FDA clearance and a manufacturing ramp-up to support anticipated commercialization. Its goal is to make insulin delivery easier and more affordable for people with diabetes, complementing the pharmaceutical advances that 501 Ventures aims to accelerate.

A Competitive Field with Many Innings to Play

The obesity and metabolic sectors are seeing renewed dealmaking activity. Pfizer recently edged out Novo Nordisk to acquire Metsera (MTSR), while AstraZeneca (AZN) exercised its option to buy SixPeaks Bio—both signaling that big pharma remains firmly in the hunt for differentiation.

Still, Conterno sees the opportunity set as just beginning. “We’ve only played the first few,” he said. “I don’t know if it’ll go to 18 innings like in the World Series, but there’s a lot of innings left to play.”

For now, 501 Ventures looks poised to step to the plate—armed with insider experience, a friendly rivalry, and a mission to fund ideas that could reshape the future of metabolic health.

The Sources

by Vista Partners LLC November 9, 2025

Obesity Drug Gold Rush: Pfizer Outbids Novo Nordisk for Metsera’s Promising Pipeline -( $PFE $MTSR $NVO $IBB $XBI )

Pfizer, never one to miss a raucous game of pharmaceutical musical chairs, has outmaneuvered Novo Nordisk in a $10 billion dash for Metsera, a company that—at the time of acquisition—boasted more promising obesity drugs in its pipeline than products on pharmacy shelves. In a market suddenly obsessed with “weight loss” instead of “blockbuster cholesterol lowering,” this deal signals Pfizer’s not-so-subtle effort to slim down its pandemic waistline while fattening up its pipeline.

A Slimmer Strategy

Metsera, the belle of this biotech ball, is a development-stage firm with no marketed products and a covetable portfolio of oral and injectable obesity treatments. Wall Street has tracked this drama like a binge-worthy miniseries: Metsera’s board cited antitrust risk in Novo Nordisk’s aggressive counter-offer, finally deeming Pfizer’s combination of cash and contingent value rights—totaling up to $86.25 a share—the “best transaction for shareholders, both in value and certainty of closing”.

Why the Rush?

The rationale is clear: Pfizer has been seeking a worthy comeback after discontinuing its own oral obesity candidate earlier this year. With Novo Nordisk and Eli Lilly vacuuming up market share with Ozempic and Wegovy, Pfizer needed a bold move to stay relevant. As CEO Albert Bourla noted, the deal “propels Pfizer into this key therapeutic area”—and, presumably, gives management one less thing to fret about at the next earnings call.

Novo’s Burning Calories

This was hardly a sleepy negotiation. Novo Nordisk raised its bid to as much as $10 billion after Pfizer’s opening play. At one point, lawsuits were flung like dumbbells at a press junket. Ultimately, Metsera’s board went with the acquirer least likely to trigger prolonged regulatory review—a decision more about legal metabolism than romance.

Pipeline: More Than Just Empty Calories

Metsera brings to Pfizer four late-stage clinical programs, including oral and injectable GLP-1 receptor agonists and amylin analog treatments aimed at monthly dosing, durability, and, just maybe, a world where weight loss drugs require less frequent injections than holiday feasts. In an industry where “pipeline” is often synonymous with “patience required,” Pfizer’s $10 billion bet is a reminder that big pharma will always chase the next big thing—ideally one that shrinks waists and grows wallets.

Shareholder Weigh-In

At last look, Pfizer shares traded just under $25, reflecting both investor optimism and skepticism—the kind of mixed reaction usually reserved for gym memberships on New Year’s Day. But with $10 billion on the line (and Novo Nordisk left holding its salad fork), Wall Street and waistlines alike will be watching to see if this deal delivers results with staying power, or just another yo-yo in the saga of pharmaceutical innovation.

The Sources

[1] Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk https://finance.yahoo.com/news/pfizer-clinches-deal-obesity-drug-173412068.html
[2] Pfizer clinches deal for obesity drug developer Metsea after a … https://abcnews.go.com/Business/wireStory/pfizer-clinches-deal-obesity-drug-developer-metsea-after-127337193
[3] Pfizer beats out Novo in bidding war for obesity-drug startup Metsera https://www.statnews.com/2025/11/07/pfizer-beats-novo-nordisk-to-acquire-metsera-obesity/
[4] Pfizer clinches deal for obesity drug developer Metsea after … – Yahoo https://www.yahoo.com/news/articles/pfizer-clinches-deal-obesity-drug-173412412.html
[5] Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-metsera-and-its-next-generation-obesity
[6] This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is … https://www.wsj.com/health/pharma/metsera-pfizer-bid-weight-loss-drugs-e95dadcc
[7] Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle https://finance.yahoo.com/news/novo-nordisk-offers-6-5-103104241.html
[8] Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio https://finance.yahoo.com/news/pfizer-acquire-metsera-next-generation-104500228.html
[11] Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal https://www.nytimes.com/2025/11/08/business/metsera-pfizer-merger-weight-loss.html
[12] Pfizer wins $10 billion bidding war for obesity drug developer https://nypost.com/2025/11/08/business/pfizer-wins-10-billion-bidding-war-for-metsera-over-novo-nordisk/
[13] Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition https://www.foxbusiness.com/fox-news-health/pfizer-wins-10b-bidding-war-obesity-drug-developer-metsera-major-pharmaceutical-acquisition
[14] Pfizer wins $10bn bidding war for weight-loss start-up Metsera https://www.ft.com/content/d9f58a26-5395-4acb-8dfc-d55cb53f946e
[15] Trump strikes deal to lower cost of Wegovy, Zepbound weight loss drugs https://www.nbcnews.com/health/health-news/trump-weight-loss-drugs-cost-wegovy-zepbound-novo-nordisk-eli-lilly-rcna242309
[16] Trump unveils deals to lower US weight-loss drug prices https://www.bbc.com/news/articles/czxk7k9nd11o
[17] Pfizer, Flagship return to obesity as part of 10-program collab https://www.fiercebiotech.com/biotech/pfizer-flagship-return-obesity-part-latest-additions-multibillion-dollar-collaboration
[18] Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion … https://finance.yahoo.com/news/pfizer-jumps-weight-loss-drug-125745662.html
[19] Pfizer – ProFound Therapeutics https://www.profoundtx.com/news-and-events/flagship-and-profound-announce-agreement-under-strategic-partnership-with-pfizer
[20] Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet https://finance.yahoo.com/video/pfizer-buy-metsera-4-9-163254233.html
[21] Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 … https://finance.yahoo.com/news/pfizer-discusses-drug-pricing-deal-162800100.html
[22] Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist

by Vista Partners LLC November 7, 2025

S&P Slides and Tech Tumbles: Wall Street’s November Nerves Unveiled -( $BLLN $INTC $LLY $MODD $VIX Rise!)

Wall Street’s week wrapped with less of a bow and more of a sigh, as major indexes retreated under a cloud of AI valuation skepticism, limp labor data, and Capitol Hill’s existential drama over the government shutdown, which cost the economy an estimated $16 billion—proving that even in politics, time is, in fact, money. Indeed, Wall Street’s latest act ended with uncertainty rather than jubilation. The pros are bracing for more volatility and, as always, waiting for the next act—with popcorn ready and a P/E ratio calculator in hand.

Major Index Performance

The tech-favored Nasdaq Composite bore the brunt, tumbling 3.04% over the last 5-days for its worst spell since March, closing at 23,004.54. The S&P 500 shed 1.63% to settle at 6,728.80, and the Dow Jones Industrial Average followed its blue-chip peers downward falling 1.21% to 46,987.10. The Russell 2000, a bellwether for small caps, joined the correction chorus as investors rotated away from speculative growth falling 1.88% to 2,432.82. The markets “fear index” The Vix closed at $19.08, +9.40% over the last 5-days.

Macroeconomic Reports

The U.S. labor market delivered more hand-wringing than high-fives, with initial jobless claims inching up to 246,000 and October hiring painted as neither hot nor cold—a market porridge unable to please anyone. ISM Manufacturing PMI shrank to 48.7, while consumer sentiment hit a three-and-a-half-year nadir, a malaise attributed to the government shutdown casting a pall over the economy.

Index Movers: Sectors and Stocks

The AI “Magnificent Seven” turned into the “Meh-gnificent Several.” Nvidia (NVDA) lost 7.08% over the last 5-days, spooked by both government reluctance to bail out the AI sector and China competition comments. Apple (AAPL), ever the calm in any storm, posted usual resilience but was ultimately dragged by sector sentiment edging down .70% to $268.47. Tesla dropped 5.92% over the last 5-days, while Elon Musk’s $1 trillion pay spectacle got approved. Broadcom (AVGO) skidded 5.46% to close on Friday at $349.43, and Meta lost about 4.11% over the last 5-days to end at $621.71 amid broader tech routs. Intel, the unexpected contrarian hero, managed a 2.39% gain over the last 5-days to end at $38.13, aided by Musk’s musings that Tesla may go steady with Intel’s chip foundries in its pursuit of autonomous vehicle glory. Palantir, despite posting a blowout quarter (EPS: $0.21 vs $0.17 expected), cratered about 11.24% over the lat 5-days to end at $177.93 as “Big Short” legend Michael Burry wagered big against it and AI exuberance deflated.

Eli Lilly rose a meaty 7.13% over the last 5-days to end at $924.37 after agreeing to U.S. pressure to cut GLP-1 drug prices—short-term pain for potential long-term market dominance, analysts wager. Oklo stumbled nearly 15.15% over the last 5-days, but remains up +430.62% YTD. Opendoor Technologies (OPEN) delivered Q3 earnings—strong on vision, faint on results, with shares little moved as Wall Street digests its tech-real-estate hybrid pitch and the stock was off 15.57% over the last 5-days ending at $6.56, but up +310% YTD.

Nokia, McDonald’s, Rio Tinto, and Oracle each experienced sector-led declines, with no earth-shaking headlines to offset the selling pressure pervasive across global equities this week.

Welcomed IPOs

It was a busy week for dealmakers and debutantes. BillionToOne (NASDAQ: BLLN) completed a $314M IPO at $60 and ended the week at $100.03, Tailwind 2.0 Acquisition Corp began trading as TDWDU, and Crown Reserve Acquisition Corp. I (CRACU) launched a $150M SPAC on Nasdaq. Harvard Ave Acquisition Corp. (HAVAU) priced its $145M IPO, also starting on the NYSE.

Tariffs and Trade

Updates on U.S.-China tariffs remained subdued this week; however, headline risk is back on the menu as politicians jostle for posturing points in the shadow of the ongoing shutdown, and no further escalation or de-escalation of trade duties was announced.

Yield Curve, Rates, and Fed Announcements

Amid the shutdown, the Fed’s “fog” on policy outlook thickened, but the yield curve steepened modestly on weaker data and haven demand. The FOMC did not convene this week, but traders are tuned to the upcoming meeting, where Powell’s every syllable will be scrutinized as if it’s the Rosetta Stone of monetary policy. The 2-yr treasury ended at 3.564% & the 10-yr ended at 4.103%.

Gold, Silver, Oil, and Crypto

When Main Street gets nervous, Gold resumes its familiar role as therapist, posting modest gains closing back above $4k at $4,009.60/oz. Silver tracked gold’s mood closing at $48.24/oz., while oil prices stabilized after a bumpy ride amid geopolitical headlines closing at $59.79 and down 2.06% over the last 5-days. Bitcoin’s price moved in sympathy with risky tech but was notably more resilient, shedding less than major equities trading at $103,828.79 Friday afternoon; crypto-related stocks largely declined, led by risk-off shifts but offset by some short-covering into Friday.

Conclusion

Wall Street’s latest act ended with uncertainty rather than jubilation. The pros are bracing for more volatility and, as always, waiting for the next act—with popcorn ready and a P/E ratio calculator in hand.bloomberg+21

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.52, +5.05% over the last 5-days), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR) and M2i Global, Inc. (MTWO) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.91 stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $36.29) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

by Vista Partners LLC November 7, 2025

The $18 Billion Oracle AI Bet: Data Centers, Bank Syndicates, and the Future of Cloud Computing -( $ORCL $GS $MUFG $AMZN $GOOG $MSFT )

A consortium of 20 major banks has just written an $18 billion check—no, that’s not a misprint—to help underwrite Oracle’s (ORCL) latest ambition: a sprawling data center campus in New Mexico that promises to give even the most jaded AI skeptic a jolt of digital optimism, or perhaps a caffeine substitute. Administrative heavyweights—Goldman Sachs (GS), Sumitomo Mitsui Banking Corp, BNP Paribas, and Mitsubishi UFJ Financial (MUFG)—are herding institutions into what’s being dubbed a “retail syndication,” where the debt will soon be sliced, diced, and distributed like so many high-tech hors d’oeuvres for late November consumption.

Oracle Bets Big, Again

Oracle, ever the goliath with a flair for audacious finance, is expected to be the main tenant for this campus, which insiders say is a jewel of the Stargate project, an AI infrastructure initiative also tied to the likes of OpenAI and SoftBank. This all-in wager on AI is, depending on your perspective, either bold leadership or an adrenaline-pumping spin at the Silicon Valley roulette wheel. As Oracle muscles into data-center arms races with established titans like Amazon’s AWS (AMZN), Google Cloud (GOOG), and Microsoft Azure (MSFT), the company’s debt profile has ballooned to the point where even sophisticated bond traders are sipping Maalox.

Financial Alchemy and Syndicate Swagger

The assembly of banks is pitching this loan as a classic project finance gambit, the sort beloved by those who wear navy suits and understand what a Piotroski F-Score is (Goldman Sachs, in particular, would like you to know its score remains robust even as it dives deeper into stable fee-based ventures). Once the ink dries, these banks plan to syndicate the debt, an act not unlike inviting the neighbors over to help finish a particularly ambitious Thanksgiving turkey—everyone gets a share, and no one wants indigestion.

AI Boom: Promise and Risk

How much debt is “too much” in the pursuit of AI-fueled greatness? Oracle apparently believes “more,” as analysts warn the company’s total obligations could approach $290 billion by 2028—enough to buy several small countries, or at least corner the global supply of ironic headlines. Meanwhile, investors keep one eye on AI’s growth metrics, and the other on Oracle’s swelling credit-default swap spreads, just in case the rocket-fueled ride gets bumpy.

Market Reaction: Stocks, Swaps, and Sarcasm

In the grand tradition of Wall Street overcorrections, Oracle’s stock has been whipsawed, while credit-default swaps on its debt now flirt at two-year highs, signaling a chilly breeze over the company’s hot AI narrative. The strategic implication? While the coffee-fueled optimism of “big data” remains, investors can’t help but wonder if too many financiers at one table is a sign of confidence, or simply a fire code violation waiting to happen.

Certainly, for Oracle and its syndicate of enablers, this $18 billion bet is the financial equivalent of parachuting into the AI wild west wearing a suit, clutching a term sheet, and hoping the future has decent Wi-Fi.

The Sources

https://www.bloomberg.com/news/articles/2025-11-07/banks-lend-18-billion-for-oracle-tied-data-center-in-new-mexico

https://finance.yahoo.com/news/banks-lend-18-billion-oracle-202012978.html

https://www.gurufocus.com/news/3196227/goldman-sachs-gs-part-of-18b-loan-for-data-center-development

https://finance.yahoo.com/news/banks-lend-18-billion-oracle-190833906.html

https://www.moomoo.com/news/post/61157456/around-20-banks-are-in-the-queue-to-provide-an

https://www.reuters.com/business/finance/five-debt-hotspots-ai-data-centre-boom-2025-11-05/

https://economictimes.com/news/international/us/oracle-default-fears-surge-as-credit-swaps-spike-to-2-year-high-is-ai-taking-its-toll/articleshow/125065038.cms

https://www.cnbc.com/2025/11/07/time-to-snap-up-oracle-now-down-more-than-30percent-in-past-two-months-says-carter-worth.html

https://www.marketscreener.com/news/banks-lend-18-billion-for-oracle-tied-data-center-project-bloomberg-news-reports-ce7d5fdad188f72d

https://www.reuters.com/business/finance/banks-lend-18-billion-oracle-tied-data-center-project-bloomberg-news-reports-2025-11-07/

https://www.computing.co.uk/news/1836465/usd103bn-oracle-acquisition-peoplesoft-confirmed

https://www.ifre.com/people-and-markets/2338177/go-big-or-go-home-why-corporate-debt-raisings-are-getting-bigger

https://www.marketbeat.com/instant-alerts/filing-1275-shares-in-oracle-corporation-orcl-acquired-by-grey-fox-wealth-advisors-llc-2025-11-07/

https://money.usnews.com/investing/news/articles/2025-11-07/banks-lend-18-billion-for-oracle-tied-data-center-project-bloomberg-news-reports

https://www.aol.com/articles/advice-dont-distracted-oracle-stocks-092500751.html

https://www.informationweek.com/it-sectors/oracle-buying-stellent-for-440-million

https://www.datacenterdynamics.com/en/news/oracle-takes-on-18bn-in-debt-ahead-of-ai-data-center-build-out/

https://www.prnewswire.com/news-releases/oracle-and-ci4cc-partner-to-accelerate-oncology-innovation-302608712.html

https://www.oracle.com/news/

https://www.marketbeat.com/instant-alerts/filing-ethos-financial-group-llc-acquires-3911-shares-of-oracle-corporation-orcl-2025-11-07/

by Vista Partners LLC November 7, 2025

JFrog’s Earnings Leap: Hopping Past Wall Street’s Cloud Rev Forecasts (and Competitors) – ( $FROG $SPY )

JFrog’s (FROG) third-quarter 2025 performance was anything but amphibious—unless “leaping” counts. The company vaulted past Wall Street forecasts, croaking out revenue of $139.6 million, soaring 26% year-over-year and leaving analysts’ modest predictions somewhere in the lily pads. Investors had reason to rejoice; shares hopped upward by more than 24% on earnings day, hitting an all-time high like a frog chasing flies at a summer barbecue.

Financial Highlights

JFrog achieved an earnings-per-share of $0.22, a 37.5% positive surprise versus forecasts—a feat that would impress even the most skeptical of market biologists.
Cloud revenue leapt by 50% over the year, now accounting for nearly half of total revenue, reflecting the ongoing migration to cloud as the modern software pond of choice.
Gross margins of 83.9% and a net dollar retention of 118% hint at strong customer loyalty—perhaps attributable to the company’s security and AI model delivery innovations, such as the new AppTrust and AI Catalog offerings.

Market Reaction and Outlook

Market participants reacted as if someone had dropped coffee into their pond: JFrog’s stock price surged, with analyst price targets quickly being revised upward—Truist Securities, for instance, hopped from $55 to $70 basically overnight. Year-to-date, shares have climbed 60%, making it one of tech’s more energetic performers. The company now forecasts full-year revenue between $523 million and $525 million, over $15 million higher than prior estimates—a signal that management expects continued upstream swimming even if macroeconomic waters get choppy.

Strategic Moves and Sophisticated Punchlines

Alongside the numbers, JFrog demonstrated it isn’t just playing leapfrog with competitors; it’s investing heavily in secure software delivery and AI integration. The poetic irony? While risk and volatility are the bane of every software supply chain, JFrog’s Riskified acquisition and product expansion suggest it’s building a moat, not a puddle.

For now, JFrog has managed to show that not all software frogs are destined for research labs—some get to sit proudly atop their pedestal, making competitors green (with envy, naturally).

The Sources

by Vista Partners LLC November 6, 2025

Tesla Shareholders Greenlight Elon Musk’s $1 Trillion Pay Jackpot—World’s First Trillionaire in the Making? -( $TSLA $SPY )

Tesla (TSLA) shareholders have given a resounding nod to CEO Elon Musk’s audacious $1 trillion pay package, a deal so outsized it makes the GDPs of small nations seem quaint by comparison. Approved by more than 75% of voters at the company’s annual meeting in Austin, this package has the potential to make Musk the world’s first trillionaire—assuming, of course, that Tesla achieves a perfect storm of self-driving cars, robotic armies, and a stock market valuation that could buy several planets.

The Magnitude of Musk’s Windfall

The newly approved plan comes with all the dramatic trappings one expects from the world’s most headline-hungry CEO. Musk’s payday—aggregating to up to $1 trillion over ten years—is staked on a series of almost Herculean targets: boosting Tesla’s valuation far beyond its current $1.4 trillion, ramping up robotaxi fleets, and launching a veritable army of Optimus robots. One can’t help but wonder if the next shareholder proposal will involve colonizing Mars in time for spring earnings.

Boardroom High Wire, Shareholder Showmanship

Tesla’s chair Robyn Denholm warned shareholders that without such an outsized incentive, Musk might wander off to develop sentient toasters or at least focus his creative energy outside the company—an argument that clearly struck a chord with investors, many of whom seem less afraid of high executive pay than of a Musk mid-life crisis. Not everyone is waxing poetic about corporate ambition, however: opposition from Norway’s sovereign wealth fund and proxy advisors—not to mention a pope—underscores that not all are charmed by Musk’s vision or his negotiation tactics.

Ambitious Goals and Quirky Ultimatums

Musk’s compensation comes with performance-based vesting, meaning he only cashes in if Tesla meets mind-boggling growth benchmarks. It’s the sort of pay-for-performance scheme that leaves many CEOs clutching their calculators and investors reaching for popcorn. Musk has previously described his need for 20% control of Tesla as an existential requirement for staying with the company—put less delicately, “if I don’t get my way, I’ll take my ball (and robots, and AI) elsewhere”.

In the end, the market itself seemed to toast the outcome, with Tesla’s shares climbing 2% on the news—perhaps already pricing in the company’s imminent acquisition of New Jersey, or at the very least the increasingly plausible robot apocalypse.

The Last Word

Whether this pay plan will be remembered as genius capitalist motivation or a billionaire’s fever dream is a tale for future historians (or the Optimus robots themselves). For now, however, the message from Tesla’s board to Musk could not be clearer: Reach the stars, but don’t forget to take the shareholders (and the company’s stock price) along for the ride.

Startup Growth That Defies Gravity

Funding Finesse and Investor FOMO

The Vibe Coding Boom—and the Sighs of Caution

Competitors and the Fight for Relevance

What’s Next For Lovable?

The Sources…

Index Performances

Macroeconomic and Fed Reports

Commodities and Crypto

Corporate News and Stock Highlights

VP Watchlist Updates

The Sources

Financing the Big “Navitas 2.0” Dream

Numbers, Volatility, and the Margins

Strategic Partners and Industry Positioning

The Sum…

The Sources

Cogent Biosciences: The Tumor Tango

GeoVax & World Immunization Day

Market Wisdom: Optimism on Tap

The Sources

From Big Pharma to Venture Capital

Betting on Early-Stage Science

The Global Hunt for Innovation

A Competitive Field with Many Innings to Play

The Sources

A Slimmer Strategy

Why the Rush?

Novo’s Burning Calories

Pipeline: More Than Just Empty Calories

Shareholder Weigh-In

The Sources

Major Index Performance

Macroeconomic Reports

Index Movers: Sectors and Stocks

Welcomed IPOs

Tariffs and Trade

Yield Curve, Rates, and Fed Announcements

Gold, Silver, Oil, and Crypto

Conclusion

VP Watchlist Updates

The Sources

Oracle Bets Big, Again

Financial Alchemy and Syndicate Swagger

AI Boom: Promise and Risk

Market Reaction: Stocks, Swaps, and Sarcasm

The Sources

Financial Highlights

Market Reaction and Outlook

Strategic Moves and Sophisticated Punchlines

The Sources

The Magnitude of Musk’s Windfall

Boardroom High Wire, Shareholder Showmanship

Ambitious Goals and Quirky Ultimatums

The Last Word

The Sources

Your Guide To Staying Informed In The Markets